FIXX News and Press, Homology Medicines Inc. From 06/10/19

- Enrollment in the pheNIX Study Marks First Gene Therapy Clinical Trial for PKU - BEDFORD, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has commenced enrollment of the Phase 1/2 pheNIX trial for...

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...

Just weeks after Homology Medicines (NASDAQ: FIXX ) received investigational new drug clearance from the US Food and Drug Administration (FDA) for its gene therapy candidate, HMI-102, the company revealed on Tuesday (May 14) that the regulatory agency has now granted the candidate fast trac...

The FDA has granted Fast Track designation to Homology Medicines' (NASDAQ: FIXX ) HMI-102, its one-time gene therapy candidate for the treatment of adults with phenylketonuria (PKU). More news on: Homology Medicines, Inc., Healthcare stocks news, Read more ...

- Company Provides Details of pheNIX, the First Gene Therapy Trial for PKU, and Remains on Track to Report Initial Clinical Results from the Phase 1/2 Study in 2019 - BEDFORD, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, a...

Homology Medicines (NASDAQ: FIXX ): Q1 GAAP EPS of -$0.64 misses by $0.11 . More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Received FDA Clearance for IND and Anticipate Starting Phase 1/2 pheNIX Trial for PKU Gene Therapy Candidate with Initial Data Expected by Year End - - Began IND-Enabling Studies for Two Additional Programs, Including First Gene Editing Program - - Strengthened Financial Pos...

BEDFORD, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate during a fireside chat at the 2019 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 1...

- Homology’s Scalable HEK293 Suspension Manufacturing Process for AAVHSCs Demonstrated Superiority to a Baculovirus System and AAVHSC15 Showed Improved In Vivo Efficacy Compared to AAV5 in PKU Model - - Non-clinical Tolerability Results of HMI-102 PKU Gene Therapy Candidate S...

BEDFORD, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data demonstrating that, with a single dose, the Company’s suite of novel adeno-associated virus vectors targeted c...